Concord Biotech Limited - Asset Resilience Ratio
Concord Biotech Limited (CONCORDBIO) has an Asset Resilience Ratio of 18.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Concord Biotech Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Concord Biotech Limited's Asset Resilience Ratio has changed over time. See CONCORDBIO net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Concord Biotech Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Concord Biotech Limited (CONCORDBIO) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs3.64 Billion | 18.0% |
| Total Liquid Assets | Rs3.64 Billion | 18.00% |
Asset Resilience Insights
- Good Liquidity Position: Concord Biotech Limited maintains a healthy 18.00% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Concord Biotech Limited Industry Peers by Asset Resilience Ratio
Compare Concord Biotech Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Concord Biotech Limited (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Concord Biotech Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 15.56% | Rs3.17 Billion ≈ $34.23 Million |
Rs20.34 Billion ≈ $220.00 Million |
-0.34pp |
| 2024-03-31 | 15.90% | Rs2.70 Billion ≈ $29.24 Million |
Rs17.01 Billion ≈ $183.93 Million |
+4.17pp |
| 2023-03-31 | 11.73% | Rs1.78 Billion ≈ $19.21 Million |
Rs15.14 Billion ≈ $163.73 Million |
-0.54pp |
| 2022-03-31 | 12.27% | Rs1.61 Billion ≈ $17.42 Million |
Rs13.13 Billion ≈ $141.97 Million |
-4.31pp |
| 2021-03-31 | 16.58% | Rs1.96 Billion ≈ $21.20 Million |
Rs11.83 Billion ≈ $127.89 Million |
-4.48pp |
| 2020-03-31 | 21.06% | Rs1.98 Billion ≈ $21.42 Million |
Rs9.41 Billion ≈ $101.71 Million |
-- |
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenola… Read more